33.02
전일 마감가:
$34.57
열려 있는:
$33.85
하루 거래량:
2.81M
Relative Volume:
1.02
시가총액:
$6.28B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-13.70
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-10.13%
1개월 성능:
-5.39%
6개월 성능:
+33.15%
1년 성능:
+10.14%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BBIO
Bridgebio Pharma Inc
|
33.02 | 6.28B | 217.77M | -438.86M | -456.33M | -2.41 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-10-03 | 개시 | Oppenheimer | Perform |
2024-09-04 | 개시 | Piper Sandler | Overweight |
2024-03-21 | 재개 | Raymond James | Outperform |
2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2023-11-07 | 개시 | Citigroup | Buy |
2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
2023-04-19 | 개시 | Evercore ISI | Outperform |
2023-02-06 | 개시 | Cowen | Outperform |
2021-12-27 | 재확인 | Mizuho | Buy |
2021-12-27 | 재확인 | SVB Leerink | Outperform |
2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
2021-05-21 | 개시 | UBS | Buy |
2021-03-22 | 재확인 | Goldman | Buy |
2021-02-22 | 재개 | JP Morgan | Overweight |
2021-02-09 | 재개 | Goldman | Buy |
2021-01-11 | 재확인 | H.C. Wainwright | Buy |
2020-12-10 | 재확인 | H.C. Wainwright | Buy |
2020-06-25 | 개시 | BofA/Merrill | Neutral |
2020-05-19 | 개시 | BTIG Research | Buy |
2020-04-13 | 개시 | H.C. Wainwright | Buy |
2020-02-19 | 개시 | Mizuho | Buy |
2019-07-26 | 개시 | Raymond James | Outperform |
2019-07-22 | 개시 | BMO Capital Markets | Outperform |
2019-07-22 | 개시 | Goldman | Buy |
2019-07-22 | 개시 | JP Morgan | Overweight |
2019-07-22 | 개시 | Jefferies | Buy |
2019-07-22 | 개시 | Piper Jaffray | Overweight |
2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada
Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan
Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener
Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com
Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - Marketscreener.com
Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India
Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
(BBIO) Technical Data - news.stocktradersdaily.com
Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN
BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India
Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
BridgeBio’s Beyonttra approved in Japan - The Pharma Letter
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq
Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - Marketscreener.com
Japan approves new ATTR-CM treatment Beyonttra - Investing.com
Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq
Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN
BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio - MSN
NYSE Content advisory: Pre-Market update + Stocks try for weekly gains - The Globe and Mail
BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights
Achondroplasia Market on Track for Major Expansion by 2034, - openPR
UBS Adjusts Price Target on BridgeBio Pharma to $65 From $62, Maintains Buy Rating - Marketscreener.com
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces CFO Succession - The Manila Times
BridgeBio Pharma Appoints New President and CFO - TipRanks
BridgeBio Pharma announces CFO succession -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
BridgeBio Pharma Names New CFO -March 17, 2025 at 04:21 pm EDT - Marketscreener.com
BridgeBio Promotes Internal Leader to CFO Role, Ensuring Strategic Continuity - StockTitan
Lobbying Update: $30,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed - Nasdaq
BridgeBio Pharma’s SWOT analysis: innovative pipeline drives stock potential - Investing.com
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock - Investing.com
Genetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - Defense World
Kkr sells $197.76 million in BridgeBio Pharma stock By Investing.com - Investing.com Australia
(BBIO) On The My Stocks Page - Stock Traders Daily
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):